Predictors of a response to cyclosporine or leukocyte removal therapy in patients with refractory ulcerative colitis

Digestive Endoscopy

Volumn 17, Issue 2, 2005, Pages 153-158

  Ando, Takafumi ^a   Watanabe, Osamu ^a   Furuta, Ryuichi ^a   Maeda, Osamu ^a   Nishio, Yuji ^a   Nishiwaki, Tsuyoshi ^a   Ina, Kenji ^a   Kusugami, Kazuo ^a   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclosporine; Leukocyte removal therapy; Steroid refractory ulcerative colitis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; STEROID;

ADULT; ANEMIA; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTAPHERESIS; DISEASE ACTIVITY; DISEASE ACTIVITY INDEX SCORE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FEVER; FOLLOW UP; HISTOLOGY; HUMAN; INTESTINE; LEUKOCYTAPHERESIS; LEUKOCYTE REMOVAL THERAPY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSAL BLEEDING; REMISSION; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS;

EID: 17644419935     PISSN: 09155635     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1443-1661.2005.00494.x     Document Type: Article

References (37)

1. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Part 1: short-term prognosis. Gut 1963; 4: 300-8.
2. Nash CL, Sutherland LR. Medical management of inflammatory bowel disease: old and new perspectives. Curr. Opin. Gastroenterol. 2001; 17: 336-41.
3. Katz JA. Advances in the medical therapy of inflammatory bowel disease. Curr. Opin. Gastroenterol. 2002; 18: 435-40.
4. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev. Gastroenterol. Disord. 2003; 3: 81-92.
5. Travis S. Recent advances in immunomodulation in the treatment of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2003; 15: 215-18.
6. Siveke JT, Folwaczny C. Medical approaches and future options in chronic active ulcerative colitis. Int. J. Colorectal Dis. 2004; 19: 297-307.
7. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am. J. Gastroenterol. 1996; 91: 1711-14.
8. Lichtiger S, Present DH. Preliminary report: cyclosporin in the treatment of severe active ulcerative colitis. Lancet 1990; 336: 16-19.
9. Lichtiger S. Cyclosporin therapy in inflammatory bowel disease: open-label experience. Mt. Sinai J. Med. 1990; 57: 315-19.
10. Santos J, Baudet S, Casellas F, Guarner L, Vilaseca J, Malagelada JR. Efficacy of intravenous cyclosporine for steroid refractory attacks of ulcerative colitis. J. Clin. Gastroenterol. 1995; 20: 285-9.
11. Cohen RD, Stein RT, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am. J. Gastroenterol. 1999; 94: 1587-92.
12. Cohen RD. Intravenous cyclosporine in severe ulcerative colitis: ready to stand alone? Gastroenterology 2001; 120: 1541-3.
13. Stack WA, Long RG, Hawkey CJ. Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment. Pharmacol. Ther. 1998; 12: 973-8.
14. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 1994; 330: 1841-5.
15. D'Haens G, Lemmens L, Geboes K et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-9.
16. van Assche G, D'Haens G, Moman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-31.
17. Sandborn WJ. Cyclosporine in ulcerative colitis: state of the art. Acta Gastroenterol Belg. 2001; 64: 201-4.
18. Yamada T, Volkmer C, Grisham MB. Antioxidant properties of 5-aminosalicylic acid: Potential mechanism for its anti-inflammatory activity. In: Williams CN (ed). Trends in Inflammatory Bowel Disease Therapy. Kluwer Academic Publishers, Boston, London. 1990; 73-84.
19. Grisham MB, Granger N. Mechanisms of neutrophil-mediated tissue injury. In: MacDermott RP, Stenson WF (eds). Inflammatory Bowel Disease. Elsevier, New York, London, Tokyo. 1992; 225-39.
20. Weissmann G. Lysosomal mechanisms of tissue injury in arthritis. N. Engl. J. Med. 1972; 286: 141-7.
21. Edwards SW, Hallett MB. Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol. Today 1997; 18: 320-4.
22. Kurtel H, Granger DN, Tso P, Grisham MB. Vulnerability of intestinal interstitial fluid to oxidant stress. Am. J. Physiol. 1992; 263: G573-8.
23. Sakai T, Kusugami K, Nishimura H et al. Interleukin 15 activity in the rectal mucosa of inflammatory bowel disease. Gastroenterology 1998; 114: 1237-43.
24. Sawada K. Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease. Dis. Colon Rectum 2003; 46: S66-77.
25. Saniabadi AR, Hanai H, Takeuchi K et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther. Apher. Dial. 2003; 7: 48-59.
26. Shirokaze J. Leukocytapheresis using a leukocyte removal filter. Ther. Apher. 2002; 6: 261-6.
27. Sawada K, Ohnishi K, Kosaka T et al. Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease. J. Gastroenterol. 1995; 30: S124-7.
28. Shimoyama T, Sawada K, Hiwatashi N et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: A multicenter study. J. Clin. Apheresis 2001; 16: 1-9.
29. Hanai H, Watanabe F, Takeuchi K et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: A prospective, uncontrolled, pilot study. Clin. Gastroenterol. Hepatol. 2003; 1: 28-35.
30. Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Batts KP, Lawson GM. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am. J. Gastroenterol. 1993; 88: 640-5.
31. Fukunaga K, Sawada K, Chikano S et al. Leukocytapheresis for ulcerative colitis. Nippon Rinsho 1999; 57: 2496-502 (in Japanese with English abstract).
32. Sawada K, Shimoyama T. Therapeutic cytapheresis for inflammatory bowel disease. Ther. Apher. 1998; 2: 90-2.
33. Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q. J. Med. 1961; 30: 393-407.
34. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8.
35. Katz S. Update in medical therapy of ulcerative colitis: a practical approach. J. Clin. Gastroenterol. 2002; 34: 397-407.
36. Sawada K, Kusugami K, Suzuki Y et al. Multicenter randomized double blind controlled trial for ulcerative colitis therapy with leukocytapheresis. Gastroenterology 2003; 124: A67-8.
37. Kashiwagi N, Sugimura K, Koiwai H et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig. Dis. Sci. 2002; 47: 1334-41.